Skip to main content

Table 3 Biomarkers in patients with clinical cure and clinical failure

From: Procalcitonin, mid-regional proadrenomedullin and C-reactive protein in predicting treatment outcome in community-acquired febrile urinary tract infection

 

Clinical cure

Clinical failure

P value

All patients (n = 249)

n = 229

n = 20

 

At presentation

 PCT

0.40 (0.13–1.54)

0.36 (0.10–1.46)

0.749

 PCT > 0.25

136 (59%)

12 (60%)

0.957

 CRP

120 (53–211)

90 (27–223)

0.851

 proADM

0.89 (0.62–1.30)

0.86 (0.67–1.20)

0.948

Day 3

 PCT

0.18 (0.07–0.87)

0.12 (0.04–0.69)

0.667

 PCT ≤ 0.25

122 (60%)

12 (67%)

0.568

 PCT ≤ 0.25 or PCT decline ≥80%

144 (71%)

14 (78%)

0.519

 proADM

0.66 (0.50–0.91)

0.63 (0.51–0.78)

0.667

Short treatment (n = 92)

n = 82

n = 10

 

At presentation

 PCT

0.34 (0.10–1.68)

0.36 (0.11–1.79)

0.980

 PCT > 0.25

47 (57%)

6 (60%)

0.871

 CRP

123 (53–194)

77 (15–142)

0.231

 proADM

0.76 (0.56–1.04)

0.85 (65–1.25)

0.360

Day 3

 PCT

0.12 (0.06–0.42)

0.13 (0.09–0.63)

0.794

 PCT ≤ 0.25

51 (66%)

7 (78%)

0.484

 PCT ≤ 0.25 or PCT decline ≥80%

62 (80%)

8 (89%)

0.542

 proADM

0.56 (0.47–0.76)

0.59 (0.53–0.74)

0.679

 Long treatment (n = 157)

n = 147

n = 10

 

At presentation

 PCT

0.48 (0.15–1.49)

0.48 (0.09–3.13)

0.826

 PCT > 0.25

89 (60%)

6 (60%)

0.973

 CRP

119 (52–224)

181 (37–263)

0.531

 proADM

0.98 (0.67–1.44)

0.86 (0.62–1.21)

0.495

Day 3

 PCT

0.22 (0.08–1.08)

0.08 (0.04–0.72)

0.358

 PCT ≤ 0.25

71 (56%)

5 (56%)

0.984

 PCT ≤ 0.25 or PCT decline ≥80%

82 (65%)

6 (67%)

0.899

 proADM

0.74 (0.53–1.03)

0.74 (0.47–1.02)

0.609

  1. Data presented as median (IQR) or number (%)
  2. CRP at presentation missing: n = 41 in short treatment and n = 41 in long treatment